v3.26.1
Sale of Future Royalties Liability (Tables)
 12 Months Ended
Dec. 31, 2025
Disclosure of financial liabilities [abstract]  
Schedule of Sale of Future Royalties Liability The following shows the activity in respect of the sale of future royalties liability:
Sale of future
royalties liability
$
Balance as of January 1, 2024
110,159
Payment from Royalty Pharma – regulatory milestone
25,000
Non-cash interest expense recognized
8,058
Balance as of December 31, 2024
143,217
Payments to Royalty Pharma
(3,456)
Non-cash interest expense recognized
43,908
Balance as of December 31, 2025
183,669
Sale of future royalties liability, current
13,247
Sale of future royalties liability, non-current
170,422